Company Description
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.
The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing.
Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2003 |
| IPO Date | Aug 21, 2018 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 344 |
| CEO | Robert Holmlin |
Contact Details
Address: 9540 Towne Centre Drive, Suite 100 San Diego, California 92121 United States | |
| Phone | 858 888 7600 |
| Website | bionano.com |
Stock Details
| Ticker Symbol | BNGO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001411690 |
| CUSIP Number | 09075F107 |
| ISIN Number | US09075F3055 |
| Employer ID | 26-1756290 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Erik Holmlin M.B.A., Ph.D. | President, Chief Executive Officer and Director and Chief Financial Officer |
| Mark Oldakowski | Chief Operating Officer |
| Dr. Alka Chaubey FACMG, Ph.D. | Chief Medical Officer |
| Mark Adamchak CPA | Vice President of Accounting and Controller |
| Jonathan Dixon J.D. | General Counsel and Secretary |
| Stanislas Marin M.B.A., M.S. | Vice President of Global Sales |
| Sheila Purim M.B.A., Ph.D. | Vice President of Global Marketing |
| Donna Polizio | Global Head of Market Access |
| Cory Kreeck | Global Head of People Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 31, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 424B5 | Filing |
| Oct 31, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 10, 2024 | 8-K | Current Report |
| Oct 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 21, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 21, 2024 | DEF 14A | Other definitive proxy statements |
| Aug 12, 2024 | EFFECT | Notice of Effectiveness |
| Aug 12, 2024 | 424B3 | Prospectus |